Epidermal Growth Factor
-
New target for colorectal cancer
Vanderbilt investigators have discovered that activated epidermal growth factor receptor may be a target for therapies to prevent colorectal cancer development. Read MoreMar 17, 2017
-
Probing mutant EGF receptor regulation
Understanding the regulation of mutant EGF receptors commonly found in lung cancers could lead to new targeted therapies. Read MoreOct 10, 2013
-
VU study identifies new mechanism for cancer development
Researchers at Vanderbilt University Medical Center led by a 32-year-old postdoctoral fellow have discovered a new mechanism for the development of cancer that is challenging conventional scientific wisdom. Read MoreJun 6, 2013
-
Stem cell population may hold colon cancer clues
Vanderbilt-Ingram Cancer Center researchers have identified a new population of intestinal stem cells that may hold clues to the origin of colorectal cancer. Read MoreMar 29, 2012
-
Stanley Cohen’s Nobel Prize: 25 years of progress
Twenty-five years after he received the Nobel Prize, Stanley Cohen’s discovery of epidermal growth factor continues to transform medicine. Read MoreDec 9, 2011